ridaforolimus
Selected indexed studies
- Ridaforolimus. (Drugs R D, 2010) [PMID:20945947]
- Clinical research progress of ridaforolimus (AP23573, MK8668) over the past decade: a systemic review. (Front Pharmacol, 2024) [PMID:38584599]
- Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies. (Future Oncol, 2011) [PMID:21732754]
_Worker-drafted node — pending editorial review._
Connections
ridaforolimus is a side effect of
Sources
- Ridaforolimus. (2010) pubmed
- Clinical research progress of ridaforolimus (AP23573, MK8668) over the past decade: a systemic review. (2024) pubmed
- Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies. (2011) pubmed
- Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas. (2013) pubmed
- Percutaneous coronary intervention with ridaforolimus eluting-stents in small vessel coronary artery disease. (2024) pubmed
- Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents: 5-Year Outcomes From the BIONICS and NIREUS Trials. (2024) pubmed
- The EluNIR(TM) Ridaforolimus Eluting Coronary Stent System. (2019) pubmed
- Risk of fatigue in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative meta-analysis. (2015) pubmed
- Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. (2013) pubmed
- Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma. (2015) pubmed